Bayer AG (FRA:BAYN) received a €124.00 ($144.19) price objective from investment analysts at Deutsche Bank AG in a note issued to investors on Friday, October 27th. The firm currently has a “buy” rating on the healthcare company’s stock. Deutsche Bank AG’s target price suggests a potential upside of 14.08% from the stock’s current price.
A number of other brokerages also recently commented on BAYN. J P Morgan Chase & Co set a €125.00 ($145.35) target price on shares of Bayer AG and gave the stock a “buy” rating in a research note on Monday, July 3rd. UBS AG set a €125.00 ($145.35) price target on shares of Bayer AG and gave the stock a “buy” rating in a report on Monday, July 3rd. BNP Paribas set a €103.00 ($119.77) price target on shares of Bayer AG and gave the stock a “neutral” rating in a report on Monday, July 3rd. Baader Bank set a €120.00 ($139.53) price target on shares of Bayer AG and gave the stock a “neutral” rating in a research note on Monday, July 3rd. Finally, Citigroup Inc. reiterated a “buy” rating on shares of Bayer AG in a research report on Wednesday, July 5th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have assigned a buy rating to the stock. Bayer AG has a consensus rating of “Buy” and a consensus target price of €122.33 ($142.25).
Shares of Bayer AG (FRA:BAYN) traded up €0.05 ($0.06) on Friday, hitting €108.70 ($126.40). The stock had a trading volume of 1,671,557 shares. Bayer AG has a one year low of €86.06 ($100.07) and a one year high of €123.82 ($143.98).
ILLEGAL ACTIVITY NOTICE: “Deutsche Bank AG Analysts Give Bayer AG (FRA:BAYN) a €124.00 Price Target” was originally reported by Week Herald and is the property of of Week Herald. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://weekherald.com/2017/11/14/deutsche-bank-ag-analysts-give-bayer-ag-bayn-a-124-00-price-target.html.
Bayer AG Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with MarketBeat.com's FREE daily email newsletter.